ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low) (SAISON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00882128
Recruitment Status : Completed
First Posted : April 16, 2009
Last Update Posted : November 17, 2009
Sponsor:
Information provided by:
AstraZeneca

Brief Summary:
To evaluate the level of control of Asthma (GINA : controlled, partially controlled, not controlled) of asthmatic patients consulting their general practitioner for a seasonal increase of respiratory symptoms (high and / or low) whether an inhaled corticotherapy is taken or not.

Condition or disease
Asthma Respiratory Symptoms

Study Type : Observational
Estimated Enrollment : 3300 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Evaluation of the Control Level (GINA) of Asthmatic Patients Consulting Their General Practitioner for a Seasonal Increase of Respiratory Symptoms (High and / or Low), Whether an Inhaled Corticotherapy is Taken or Not
Study Start Date : May 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Group/Cohort
1



Primary Outcome Measures :
  1. Evaluate the control level of Asthma of asthmatic patients consulting their GP for a seasonal increase of respiratory symptoms (high/low) with an inhaled corticotherapy or not. [ Time Frame: One shot (patients will only have one visit to attend - this visit will take place between May 09 and September 09) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The first 3 consecutive adult and asthmatic patients consulting their general practitioner for a seasonal increase of respiratory symptoms (high and / or low) and treated with PRN fast acting bronchodilatator alone or associated with inhaled IGCS, excluding all other treatments for asthma.
Criteria

Inclusion Criteria:

  • Asthmatic adults consulting for a seasonal increase of respiratory symptoms (high/low) and treated with PRN fast acting bronchodilator alone or associated with inhaled IGCS, excluding all other treatments for asthma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00882128


  Show 1054 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne Castaigne AstraZeneca

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00882128     History of Changes
Other Study ID Numbers: NIS-RFR-DUM-2008/2
First Posted: April 16, 2009    Key Record Dates
Last Update Posted: November 17, 2009
Last Verified: November 2009

Keywords provided by AstraZeneca:
Asthma seasonal respiratory symptoms
Asthmatic patients with increase of respiratory symptoms

Additional relevant MeSH terms:
Asthma
Signs and Symptoms, Respiratory
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Signs and Symptoms